Stock BMND.F BIOMIND LABS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Biomind Labs Inc.

Equities

BMND.F

CA0907021012

End-of-day quote OTC Markets
Other stock markets
 03:30:00 25/06/2024 am IST 		5-day change 1st Jan Change
0.1633 USD +43.12% Intraday chart for Biomind Labs Inc. +43.12% +63.30%
31/05 Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canadian Investment Regulatory Organization Trade Resumption - BMND
AQ
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Canadian Investment Regulatory Organization Trading Halt - BMND
AQ
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
BU
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
CI
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
An unknown buyer acquired 27.09% stake in Biomind Labs Inc. (OTCPK:BMND.F) from Union Acquisition Group, LLC for $14.1 million.
CI
Biomind Labs Inc. Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’S Disease with A Proprietary Formulation Based on 5-Meo-Dmt
CI
Biomind Labs Inc. Auditor Raises 'Going Concern' Doubt
CI
Biomind Labs Announces the Completion of the First Sublingual Formulation for Its BMND08 Candidate for Depression and Anxiety in Alzheimer's Disease
AQ
Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease
CI
Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression
CI
Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant Depression
CI
Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant Depression
CI
Biomind and Queen's University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System
AQ
Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery System
CI
Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant Depression
CI
Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease
CI
Crosswinds Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMND.F Stock
  4. News Biomind Labs Inc.